← Back to Search

CAR T-cell Therapy

Neuropsychological Testing for Aggressive Lymphoma

N/A

Waitlist Available

Led By Brian Scott, MD

Research Sponsored by Stanford University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age >/= 18 years-old

Able to attend and participate in in-person testing (Arm I)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 months

Awards & highlights

Study Summary

This trial will test if a new cancer treatment improves the thinking skills of patients.

Who is the study for?

This trial is for adults over 18 who've had Axicabtagene ciloleucel CAR-T therapy for aggressive lymphoma. Participants must be fluent in English, able to attend in-person or remote testing with good internet and a computer, and at least 6 months post-CAR-T infusion. Those with severe cognitive/physical limitations, active chemotherapy treatment, progressive cancer, or enrolled in another CAR-T study can't join.Check my eligibility

What is being tested?

The study is evaluating the long-term effects of CAR-T therapy on brain function by using neuropsychological tests. It will measure how well participants think and process information after their treatment at Stanford.See study design

What are the potential side effects?

Since this trial involves neuropsychological testing rather than drug interventions, there are no direct side effects from medications being studied. However, the process may cause fatigue or stress.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I can go to the clinic for tests.

Select...

It has been 6 months or more since my CAR-T cell therapy.

Select...

I have received Axicabtagene ciloleucel CAR-T therapy.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of patients who complete neuropsychological testing in the post-CAR-T adult population

Number of patients who complete telehealth neuropsychological testing in the post-CAR-T adult

Secondary outcome measures

Clock Drawing Test

Controlled Oral Work Association Test COWAT

Digit Span

+6 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Neuropsychological testingExperimental Treatment1 Intervention

Participants will take neuropsychological testing in-person or via telehealth video

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Neuropsychological testing

2017

N/A

~570

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor

2,386 Previous Clinical Trials

17,333,988 Total Patients Enrolled

Brian Scott, MDPrincipal InvestigatorStanford University

Media Library

Axicabtagene ciloleucel (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05416554 — N/A

Non-Hodgkin's Lymphoma Research Study Groups: Neuropsychological testing

Non-Hodgkin's Lymphoma Clinical Trial 2023: Axicabtagene ciloleucel Highlights & Side Effects. Trial Name: NCT05416554 — N/A

Axicabtagene ciloleucel (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05416554 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this trial currently enrolling participants?

"Data hosted on clinicaltrials.gov displays that this medical study is not currently looking for participants. The trial was initially uploaded to the site on February 1st 2023, and most recently revised November 9th 2022; however, there are 1,766 other trials actively recruiting patients at present."

Answered by AI

What is the ultimate aim of this research endeavor?

"The primary objective of this study, monitored over the course of six months, is to acquire data on the number of patients who finish neuropsychological testing in a post-CAR-T adult population. Secondary outcomes that will be measured are Trails A and B (Oral Trials) which evaluates language and processing speed deficits, Digit Span which measures executive functioning and visuospatial abilities against age/education matched norms, as well as General Anxiety Disorder Assessment GAD-7 for assessing anxiety from mild to severe levels."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford

2024. "Long-term Cognitive, Neuropsychiatric and Functional Outcomes in Adults Who Have Received Chimeric Antigen-Receptor T-Cell (CAR-T) Therapy for Aggressive Lymphoma at Stanford". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05416554.